ALLEGAN — Store-brand products maker Perrigo Co. said Friday that it has filed an Abbreviated New Drug Application to market a generic, over-the-counter version of heartburn treatment Zegerid.
The product is for the treatment of frequent heartburn.
Perrigo’s product will be a generic equivalent to Schering-Plough’s Zegerid-OTCTM, a proton pump inhibitor (a drug that causes a significant reduction of gastric acid) and an antacid.
In a statement, Perrigo said annual sales of the over-the-counter name-brand treatment are estimated to be about $60 million.
Even if approval is granted by the U.S. Food and Drug Administration, legal action is pending. Schering-Plough filed suit in September alleging Perrigo’s product will infringe on its patent. Santarus Inc. and the Curators of the University of Missouri, the licensor and owner of the patents, are co-plaintiffs in the lawsuits.
No comments:
Post a Comment